MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.5300
-0.0100 (-0.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.5400
Open1.5300
Bid1.4300 x 46000
Ask1.5300 x 27000
Day's Range1.4600 - 1.5678
52 Week Range0.9400 - 3.0400
Volume1,960,730
Avg. Volume3,095,441
Market Cap287.294M
Beta (3Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-0.6030
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

    If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live.  To access the webcast, please visit www.hcwevents.com.  Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.  The webcast replay will remain available for 14 days following the live presentation.

  • GlobeNewswire20 days ago

    MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

    MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.  Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.  Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones.  MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.

  • Analysts Give Positive Recommendations to MannKind in March
    Market Realist25 days ago

    Analysts Give Positive Recommendations to MannKind in March

    How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March

  • MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
    Market Realistlast month

    MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According

  • MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
    Market Realistlast month

    MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3

  • What Analysts Are Recommending for MannKind and Akebia in March
    Market Realistlast month

    What Analysts Are Recommending for MannKind and Akebia in March

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower

  • GlobeNewswirelast month

    MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly

    MannKind Corporation (MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda.

  • ACCESSWIRElast month

    These Four Healthcare Stocks Are Making Moves on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNKD earnings conference call or presentation 26-Feb-19 2:00pm GMT

    Q4 2018 MannKind Corp Earnings Call

  • Zacks Small Cap Research2 months ago

    MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results

    The results for Q4 and the full year 2018 from MannKind Corp. (MNKD) were a pleasant surprise. MNKD also received a milestone payment of $10 million, which reflects $6.4M under the United Therapeutics (UTHR) license agreement, $3.8M from the UT research agreement and $0.1M from the Cipla marketing and distribution agreement. On the earnings call, management shared results related to Afrezza’s quarterly prescription growth since 2017.

  • MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript

    MNKD earnings call for the period ending December 31, 2018.

  • Here's Why MannKind Rocketed Higher Today
    Motley Fool2 months ago

    Here's Why MannKind Rocketed Higher Today

    Shares jumped after the company reported upbeat fourth-quarter results. Here's what investors need to know.

  • GlobeNewswire2 months ago

    MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call

    Conference Call to Begin Today at 9:00 AM ET 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q.

  • ACCESSWIRE2 months ago

    MannKind Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / MannKind Corporation (NASDAQ: MNKD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 9:00 ...

  • Benzinga2 months ago

    Q4 Earnings Outlook For MannKind

    On Tuesday, Feb. 26, MannKind (NASDAQ: MNKD ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Analysts are expecting MannKind to report a loss ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...

  • GlobeNewswire2 months ago

    MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

    WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation.

  • GlobeNewswire2 months ago

    MannKind Corporation Participating at Upcoming Conferences

    WESTLAKE VILLAGE, Calif., Feb. 20, 2019 -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • GlobeNewswire2 months ago

    MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019

    WESTLAKE VILLAGE, Calif., Feb. 19, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019.

  • GuruFocus.com2 months ago

    Weekly CFO Buys Highlight

    Insiders pile on shares of Dynex Capital, MannKind and Martin Midstream Partners

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Zacks Small Cap Research3 months ago

    MNKD: Update From Our Meeting With MNKD at JPM

    The International Diabetes Federation’s (IDF) Diabetes Atlas (8th edition) has estimated that approximately 30 million people were living with diabetes in 2017 in the U.S. According to the CDC, about 1.5 million new cases are diagnosed per year. Although insulin injection pens are ubiquitous and generally convenient to carry around, adherence to therapy has remained a challenge primarily due to hypo/hyperglycemia and, to some extent, as a result of anxiety associated with an injection, local sensitivity, pain and bruising. One of the biggest challenges for the company has been accelerating growth of Afrezza.

  • ACCESSWIRE3 months ago

    Biotech Stocks on the Move

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...

  • GlobeNewswire3 months ago

    MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $4 a day.